Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa open-label multidose study of IPG11406 in systemic lupus erythematosus with nephritis
CTR20244487Phase 2Completed
- Sponsor
- Aimed Bio
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IPG11406 in systemic lupus erythematosus (SLE), sponsored by Aimed Bio. Started Feb 2025; status: completed.
02
Drugs
IPG11406
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20244487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244487.